A randomized controlled trial evaluating the impact of selective axillary nerve block after arthroscopic subacromial decompression

Table 2 Outcomes after selective axillary nerve block

	Ropivacaine	Placebo	P
Primary outcomes
Intravenous morphine 0–4 h, mg ITT	14 (0–35)	18 (2–34)	0.12
Intravenous morphine 0–4 h, mg PPA^a	16 (0–35)	18 (2–34)	0.40
Secondary outcomes
Pain (rest) 0–4 h, VAS measured as AUC^b	135 (4–293)	182 (15–383)	0.030^*
Pain (rest) 8 h, VAS^b	9 (0–26)	20 (0–67)	0.01^*
Pain (rest) 24 h, VAS^b	7 (0–25)	18 (0–45)	0.04^*
Oral morphine 4–24 h, mg^b	0 (0–20)	10 (0–30)	0.25
Escape block (number of patients)	10 of 27 (37%)	4 of 23 (17%)	0.21
Nausea and vomiting 0–4 h^c	2 of 16 (13%)	4 of 18 (22%)	0.66

Values are medians and (range). ITT intention to treat analysis, PPA per protocol analysis, VAS visual analogue scale and AUC area under the curve
^*P < 0.05
^aPatients with unsuccessful nerve block removed from analysis (8 ropivacaine, 0 placebo)
^bPatients with escape block was removed from analysis (10 ropivacaine, 4 placebo group)
^dTwo patients in the ropivacaine group had missing data

ISSN: 1471-2253